Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men after a National Female Vaccination Program

Journal of Infectious Diseases

Volumn 215, Issue 2, 2017, Pages 202-208

  Machalek, Dorothy A ^a,b   Chow, Eric P F ^c,e   Garland, Suzanne M ^a,b,d   Wigan, Rebecca ^c   Cornall, Alyssa M ^a,b,d   Fairley, Christopher K ^c,e   Kaldor, John M ^g   Hocking, Jane S ^f   Williams, Henrietta ^c,e   McNulty, Anna ^h   Bell, Charlotte ^j   Marshall, Lewis ^k   Ooi, Catriona ⁱ   Chen, Marcus Y ^c,e   Tabrizi, Sepehr N ^a,b,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h Sydney Sexual Health Centre   (Australia)

ⁱ WESTERN SYDNEY SEXUAL HEALTH CENTRE   (Australia)

^j ROYAL ADELAIDE HOSPITAL   (Australia)

^k FREMANTLE HOSPITAL   (Australia)

more..

Author keywords

Herd effects; Herd protection; Heterosexual; HPV; human papillomavirus; Males; Prevalence; Vaccine

Indexed keywords

ADOLESCENT; ADULT; AUSTRALIA; CLASSIFICATION; FEMALE; GENETICS; HETEROSEXUALITY; HUMAN; ISOLATION AND PURIFICATION; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PENIS; PREVALENCE; PREVENTIVE HEALTH SERVICE; QUESTIONNAIRE; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AUSTRALIA; FEMALE; HETEROSEXUALITY; HUMANS; IMMUNIZATION PROGRAMS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENIS; PREVALENCE; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85021857813     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw530     Document Type: Article

References (39)

1. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction-The first five years. Vaccine 2012; 30(suppl 5):F139-48.
2. de Sanjose S, Alemany L, Ordi J, et al.Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013; 49:3450-61.
3. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048-56.
4. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30(suppl 5):F12-23.
5. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: Analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199:805-14.
6. Brotherton JM. Human papillomavirus vaccination: where are we now? J Paediatr Child Health 2014; 50:959-65.
7. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 2016; 137:1-9.
8. Gertig DM, Brotherton JM, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011; 8:171-8.
9. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346:f2032.
10. Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: Analysis of routinely collected national hospital data. J Infect Dis 2015; 211:91-9.
11. Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-Analysis. Lancet Infect Dis 2015; 15:565-80.
12. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: A repeat cross-sectional study. Lancet Infect Dis 2014; 14:958-66.
13. Hariri S, Bennett NM, Niccolai LM, et al. Reduction in HPV 16/18-Associated high grade cervical lesions following HPV vaccine introduction in the United States-2008-2012. Vaccine 2015; 33:1608-13.
14. Chow EP, Read TR, Wigan R, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2015; 91:214-9.
15. Chow EP, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccine targeted human 44 papillomavirus genotypes in heterosexual men following the Australian female HPV 45 vaccination programme: An observational study from 2004 to 2015. Lancet Infect Dis 2016; doi:10.1016/S1473-3099(16)30116-5.
16. Fenner Y, Garland SM, Moore EE, et al. Web-based recruiting for health research using a social networking site: An exploratory study. J Med Internet Res 2012; 14: e20.
17. Osborne SL, Tabrizi SN, Brotherton JM, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine 2015; 33:201-8.
18. Giuliano AR, Nielson CM, Flores R, et al. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: The HPV detection in men study. J Infect Dis 2007; 196:1146-52.
19. Hernandez BY, McDuffie K, Goodman MT, et al. Comparison of physician-And self-collected genital specimens for detection of human papillomavirus in men. J Clin Microbiol 2006; 44:513-7.
20. Hernandez BY, Wilkens LR, Unger ER, et al. Evaluation of genital self-sampling methods for HPV detection in males. J Clin Virol 2013; 58:168-75.
21. Resnick RM, Cornelissen MT, Wright DK, et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990; 82:1477-84.
22. Cornall AM, Roberts JM, Garland SM, Hillman RJ, Grulich AE, Tabrizi SN. Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11. Int J Cancer 2013; 133:2253-8.
23. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38:357-61.
24. Layton-Henry J, Scurry J, Planner R, et al. Cervical adenoid basal carcinoma, five cases and literature review. Int J Gynecol Cancer 1996; 6:193-9.
25. Stevens MP, Garland SM, Tabrizi SN. Development and validation of a real-Time PCR assay specifically detecting human papillomavirus 52 using the Roche Light-Cycler 480 system. J Virol Methods 2008; 147:290-6.
26. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711-23.
27. Rissel C, Badcock PB, Smith AM, et al. Heterosexual experience and recent heterosexual encounters among Australian adults: The Second Australian Study of Health and Relationships. Sex Health 2014; 11:416-26.
28. Chow EP, Read TR, Law MG, Chen MY, Bradshaw CS, Fairley CK. Assortative sexual mixing patterns in male-female and male-male partnerships in Melbourne, Australia: implications for HIV and sexually transmissible infection transmission. Sex Health 2016; doi:10.1071/SH16055.
29. Brotherton JM, Liu B, Donovan B, Kaldor JM, Saville M. Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. Vaccine 2014; 32:592-7.
30. Coutinho LM, Scazufca M, Menezes PR. Methods for estimating prevalence ratios in cross-sectional studies. Rev Saude Publica 2008; 42:992-8.
31. Brotherton J, Gertig D, Chappell G, Rowlands L, Saville M. Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register. Commun Dis Intell Q Rep 2011; 35:197-201.
32. Giuliano AR, Lee JH, FulpW, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): A cohort study. Lancet 2011; 377:932-40.
33. Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of human papillomavirus infection in males: A global review. J Adolesc Health 2011; 48:540-52.
34. Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:2036-43.
35. Garland SM, Molesworth EG, Machalek DA, Cornall AM, Tabrizi SN. How to best measure the effectiveness of male human papillomavirus vaccine programmes? Clin Microbiol Infect 2015; 21:834-41.
36. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: A systematic review and meta-Analysis. Lancet Oncol 2012; 13:487-500.
37. Zou H, Tabrizi SN, Grulich AE, et al. Early acquisition of anogenital human papillomavirus among teenage men who have sex with men. J Infect Dis 2014; 209:642-51.
38. Georgousakis M, Jayasinghe S, Brotherton J, Gilroy N, Chiu C, Macartney K. Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Lancet Infect Dis 2012; 12:627-34.
39. World Health Organization, Department of Immunization, Vaccines and Biologicals. Report of the meeting on HPV Vaccine Coverage and Impact Monitoring. http://apps.who.int/iris/bitstream/10665/70305/1/WHO-IVB-10.05-eng.pdf. Accessed 5 March 2016